News

RIFF Cannabis Brand Launches New THC Beverages for Summer

New RIFF Wild Raspberry Lemonade and RIFF Blue Raspberry Ice Sparkling Drinks Infused with 10mg of THC, Crafted for #RefreshmentElevatedTORONTO,…

2 years ago

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical…

2 years ago

Evelo Biosciences Closes $25.5 Million Private Placement

Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of…

2 years ago

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocolQ2 2023 consolidated revenue were affected by specialty…

2 years ago

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Accomplished Industry Veteran Brings Deep Strategic and Operational ExpertiseCAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq:…

2 years ago

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a…

2 years ago

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled…

2 years ago

Tilray Brands, Inc. to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on July 26, 2023

NEW YORK and LEAMINGTON, Ontario, July 12, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;…

2 years ago

Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.

The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to…

2 years ago

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern TimeNEW YORK, July 12,…

2 years ago